0001140361-16-088115.txt : 20161129
0001140361-16-088115.hdr.sgml : 20161129
20161129200749
ACCESSION NUMBER: 0001140361-16-088115
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161121
FILED AS OF DATE: 20161129
DATE AS OF CHANGE: 20161129
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348911
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200915291
FISCAL YEAR END: 0430
BUSINESS ADDRESS:
STREET 1: BUILDING 227, TETRICUS SCIENCE PARK
STREET 2: PORTON DOWN
CITY: SALISBURY, WILTSHIRE
STATE: X0
ZIP: SP4 0JQ
BUSINESS PHONE: 44 0 1980 753002
MAIL ADDRESS:
STREET 1: BUILDING 227, TETRICUS SCIENCE PARK
STREET 2: PORTON DOWN
CITY: SALISBURY, WILTSHIRE
STATE: X0
ZIP: SP4 0JQ
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Therapeutics, Inc.
DATE OF NAME CHANGE: 20140916
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery, Inc
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Carbylan Biosurgery Inc
DATE OF NAME CHANGE: 20060105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Resnick Joshua
CENTRAL INDEX KEY: 0001690959
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36830
FILM NUMBER: 162023841
MAIL ADDRESS:
STREET 1: ONE BOSTON PLACE
STREET 2: 201 WASHINGTON STREET, SUITE 3900
CITY: BOSTON
STATE: MA
ZIP: 02108
4
1
doc1.xml
FORM 4
X0306
4
2016-11-21
0
0001348911
KalVista Pharmaceuticals, Inc.
KALV
0001690959
Resnick Joshua
ONE BOSTON PLACE, SUITE 3900
201 WASHINGTON STREET, SUITE 3900
BOSTON
MA
02108
1
0
0
0
Common Stock
2016-11-21
4
A
0
2508279
A
2508279
I
By SV Life Sciences Fund IV, L.P.
Common Stock
2016-11-21
4
A
0
71211
A
71211
I
By SV Life Sciences Fund IV Strategic Partners, L.P.
Received in exchange for 6,730,810 shares of KalVista Pharmaceuticals, Ltd. Series A Preferred Shares and 1,885,228 shares of Series B Preferred Shares in connection with the closing of the share purchase transaction (the "Transaction") whereby KalVista Pharmaceuticals, Ltd. became a wholly-owned subsidiary of Carbylan Therapeutics, Inc., which changed its name to KalVista Pharmaceuticals, Inc. (the "Company"). On the effective date of the Transaction, the closing price of the Company's common stock was $9.38 per share. All numbers give effect to the 14:1 reverse stock split effected by the Company on November 21, 2016 (the "Reverse Stock Split"). Prior to the Reverse Stock Split, the closing price of the Company's common stock was $0.67 per share.
SV Life Sciences Fund IV Strategic Partners, L.P., a Delaware limited partnership, and (ii) SV Life Sciences Fund IV, L.P., a Delaware limited partnership. The general partner of both SV Life Sciences Fund IV, L.P. and SV Life Sciences Fund IV Strategic Partners, L.P. (collectively, the "Funds") is SV Life Sciences Fund IV (GP), L.P. The general partner of SV Life Sciences Fund IV (GP), L.P. is SVLSF IV, LLC. Both SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC may be deemed to beneficially own the shares held by the Funds. SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC may be deemed to beneficially own the shares held by the Funds. SV Life Sciences Fund IV (GP), L.P. and SVLS IV, LLC disclaim beneficial ownership of the shares held by the Funds except to the extent of any pecuniary interest therein. Dr. Resnick, a director of Issuer, is a partner of SV Life Sciences.
Received in exchange for 191,091 shares of KalVista Pharmaceuticals, Ltd. Series A Preferred Shares and 53,523 shares of Series B Preferred Shares in connection with the closing of the Transaction. On the effective date of the Transaction, the closing price of the Company's common stock was $9.38 per share. All numbers give effect to the Reverse Stock Split. Prior to the Reverse Stock Split, the closing price of the Company's common stock was $0.67 per share.
/s/Joshua Resnick
2016-11-29